Drug Interactions of Anagrelide

When seeking medical consultation and receiving new prescription drugs, proactively inform your doctor that you are currently taking anagrelide. This includes medications prescribed by dentistry, ophthalmology, and dermatology, as well as over-the-counter traditional Chinese medicine and health supplements you purchased yourself.

Drug Interactions of Anagrelide

1. Drugs that May Prolong the QT Interval

Concomitant use with anagrelide should be avoided. The list includes chloroquine, clarithromycin, haloperidol, methadone, moxifloxacin, amiodarone, disopyramide, procainamide, and pimozide, among others.

2. Other PDE3 Inhibitors and Positive Inotropic Agents

Medications such as cilostazol and milrinone should also be avoided in combination, as they may aggravate the positive inotropic effect.

3. Drugs Increasing Bleeding Risk

Risk-benefit evaluation and monitoring for bleeding are required. This includes aspirin (key point), anticoagulants, other PDE3 inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), antiplatelet drugs, and selective serotonin reuptake inhibitors (SSRIs, such as sertraline and paroxetine).

4. Interactions via CYP1A2 Metabolism

CYP1A2 inhibitors, such as fluvoxamine and ciprofloxacin, may increase exposure to anagrelide; cardiovascular events should be monitored and doses adjusted accordingly. CYP1A2 inducers, such as omeprazole, may decrease exposure to anagrelide, which may require dose adjustment in patients. Although anagrelide exhibits limited CYP1A2 inhibitory activity in vitro, it may still alter exposure to co-administered drugs (such as theophylline, fluvoxamine, and ondansetron). Anagrelide is sensitive to this pathway because it is primarily metabolized by CYP1A2 to the active metabolite 3-hydroxy-anagrelide, which is further metabolized by CYP1A2 to the inactive product RL603.

5. Combinations with Relatively Fewer Concerns (Pharmacokinetics Only)

In vivo studies show that anagrelide does not affect the pharmacokinetic profile of digoxin or warfarin, nor do digoxin or warfarin affect the pharmacokinetics of anagrelide. However, this conclusion is limited to the pharmacokinetic level and does not imply that bleeding monitoring is unnecessary when co-administered.

6. Aspirin

Before initiating treatment, the potential risks and benefits of combining anagrelide with aspirin should be evaluated, with particular caution in populations at high risk of bleeding.

Do not start taking aspirin on your own (including low-dose enteric-coated tablets for "cardiovascular prevention"). If your doctor deems it necessary for you to take both, ensure that the doctor is aware you are currently taking anagrelide and agree upon a bleeding monitoring plan.

Friendly Reminder: Before undergoing any surgery, tooth extraction, gastroscopy/colonoscopy biopsy, or other invasive procedures, proactively inform the surgeon, anesthesiologist, and performing physician that you are taking anagrelide.